H-Index
10
Scimago Lab
powered by Scopus
eISSN: 2325-4416
call: +1.631.470.9640
Mon-Fri 10 am - 2 pm EST

Logo

MSMbanner
AmJCaseRep

Annals
ISI-Home

Cabozantinib, a Novel c-Met Inhibitor, Inhibits Colorectal Cancer Development in a Xenograft Model

Yinggang Sun, Liyong Sun, Yanxin An, Xin Shen

Department of General Surgery, Jinan Military General Hospital, Jinan, Shandong, China (mainland)

Med Sci Monit 2015; 21:2316-2321

DOI: 10.12659/MSM.893590

Available online:

Published: 2015-08-08


BACKGROUND: Angiogenesis plays a critical role during tumor development. c-Met has recently been implicated in the angiogenesis of various tumors, leaving its role in colorectal cancer (CRC) unknown. In this study, we aimed to evaluate the effect of a novel c-Met inhibitor, cabozantinib, on the tumor growth and angiogenesis in a CRC mouse model.
MATERIAL AND METHODS: A mouse CRC xenograft model was used to evaluate the effect of cabozantinib on vivo growth of tumors and angiogenesis. The expression of angiogenesis-related factors was evaluated by immunohistochemistry (IHC) and Western blotting. Levels of serum cytokines were detected by ELISA.
RESULTS: Cabozantinib effectively reduced tumor size and angiogenesis, and suppressed the expression of vascular endothelial growth factor (VEGF) in tumor tissues, possibly via the inhibition of Sonic Hedgehog (SHH) pathway.
CONCLUSIONS: The blockade of c-Met inhibits the tumor growth and angiogenesis via modulating SHH pathway, suggesting a potential strategy in the treatment of CRC.

Keywords: Animals, Anilides - therapeutic use, Colorectal Neoplasms - prevention & control, Cytokines - metabolism, Inflammation Mediators - metabolism, Mice, Mice, Inbred BALB C, Neovascularization, Pathologic - prevention & control, Proto-Oncogene Proteins c-met - antagonists & inhibitors, Pyridines - therapeutic use, Signal Transduction, Xenograft Model Antitumor Assays



Back